Ascendis Pharma (ASND) PT Raised to $225 at Goldman Sachs
Tweet Send to a Friend
Goldman Sachs analyst Paul Choi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $225.00 (from $200.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
